DDInter1568 DDInter1676
Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ranitidine {u} (Compound) resembles {v} (Compound) Nizatidine
Ranitidine {u} (Compound) binds {v} (Gene) CYP3A4
Ranitidine {u} (Compound) upregulates {v} (Gene) GPATCH8
Ranitidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Ranitidine {u} (Compound) downregulates {v} (Gene) SDC1
Ranitidine {u} (Compound) causes {v} (Side Effect) Weight decreased
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etodolac
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tubocurarine
Ranitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ranitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Ranitidine (Compound) resembles Nizatidine (Compound)
Ranitidine (Compound) binds CYP3A4 (Gene)
Ranitidine (Compound) upregulates GPATCH8 (Gene)
Ranitidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Ranitidine (Compound) downregulates SDC1 (Gene)
Ranitidine (Compound) causes Weight decreased (Side Effect)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Etodolac
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Tubocurarine
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline